Pharmacogenomics & Precision Medicine

September 2, 2021

Study shows gene-drug interactions are common

When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.

By Paul Govern
From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

By Bill Snyder
March 15, 2021

Roden honored with Oscar B. Hunter Career Award in Therapeutics

Dan Roden, MD, Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center, received the Oscar B. Hunter Career Award in Therapeutics last week at the virtual annual meeting of the American Society for Clinical Pharmacology and Therapeutics.

By Leigh MacMillan
Medical laboratory scientist Gladys Garrison, MT, MS, loads reagents to prepare DNA samples for analysis in the VUMC Molecular Diagnostics Lab.
April 30, 2020

PREDICT program expands, opens new Genomics Clinic

A new clinic opening at Vanderbilt University Medical Center will help doctors and patients choose the best drugs for their medical conditions based on the patients’ unique genetic makeup.

By Bill Snyder
November 6, 2019

Study finds acid reducers may pose risk for children

The use of acid reducers among children is on the rise and so are potential side effects, which is sparking concern according to a recent study.

By Jessica Pasley
January 25, 2018

Personalized drug prescribing program expands, upgrades

Vanderbilt University Medical Center (VUMC) has expanded and relaunched genetic testing to predict patient responses to drugs.

By Paul Govern
March 31, 2016

Study looks at doctors’ response to genetic testing

A new clinical implementation study from Vanderbilt University Medical Center measures how physicians have responded to the introduction of routine genetic testing to predict patient response to the commonly prescribed antiplatelet drug clopidogrel.
By Paul Govern
July 9, 2015

VUMC lands major pharmacogenomics grant

Vanderbilt University Medical Center has received a five-year, $12.8 million grant from the federal government to develop better ways to predict how patients will respond to the drugs they’re given.
By Bill Snyder
February 6, 2014

PREDICT program lands informatics innovation award

Healthcare Informatics Magazine has awarded Vanderbilt University Medical Center third place in its 2014 Innovator Awards.
By Paul Govern
October 17, 2013

Pharmacogenomic testing costs studied

A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions.
By Paul Govern
August 15, 2013

Transplant drug added to PREDICT program

Tacrolimus is essential for patients receiving new hearts, kidneys and other organ transplants. The drug suppresses the body’s immune system, helping to prevent rejection.
By Bill Snyder
November 1, 2012

Patients’ genetic data helps hone warfarin dosing

Warfarin dosing at Vanderbilt University Medical Center just got safer and more effective.
By Paul Govern
October 4, 2012

PREDICT helps pinpoint right statin for patient

When O.T. Hayes, 67, of Lebanon, Tenn., first starting seeing his cardiologist, David Hansen, M.D., for treatment of his coronary artery disease, it was hard to predict which of the various medications available would help control Haynes’ high cholesterol.
By Kathy Whitney